Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults
NCT ID: NCT04583007
Last Updated: 2023-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NO_LONGER_AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis
NCT04861090
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
NCT05469789
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II
NCT04130191
A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
NCT05147181
A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children
NCT04070326
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lanadelumab 150 mg
TAK-743-6001: Participants will receive subcutaneous (SC) injection of lanadelumab at a dose of 150 milligrams (mg) at the same frequency (for every 2 weeks \[Q2W\] or for every 4 weeks \[Q4W\]) given at the completion of SPRING study until benefit-risk no longer favors the individual participant or an appropriate alternative therapy becomes available or lanadelumab 150 mg/ 1 milliliter (mL) becomes commercially available or the participants turns 12 years of age or participant chooses to discontinue treatment. For participants aged 6-12 years, a dose frequency may be modified based on a benefit-risk assessment and medical decision from the treating physician.
Lanadelumab 300 mg
TAK-743-5012: Participants will receive SC injection of lanadelumab in prefilled syringe at a dose of 300 mg, Q2W or Q4W if well controlled for 26 weeks across Study TAK-743-3001 and this (TAK-743-5012) program.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pediatric participants, 2 to \<12 years of age, with HAE who completed the SHP643-301 (SPRING) study and are deriving continued clinical benefit from lanadelumab treatment will be invited to take part in this program
* Participants have no suitable alternative treatment options and cannot enter a lanadelumab clinical trial
* Participant has a parent(s)/legal guardian who is informed of the nature of the expanded access program and can provide written informed consent for the child to participate (with assent from child when appropriate) prior to treatment
* Participants does not have any of the following liver function test abnormalities : alanine aminotransferase (ALT) greater than (\>)3x upper limit of normal (ULN), or aspartate aminotransferase (AST) \>3x ULN, or total bilirubin \>2x ULN (unless the bilirubin elevation is a result of Gilbert's syndrome)
* Participant does not have any condition that in the opinion of the Investigator may compromise their safety
* Participant does not have a known hypersensitivity to lanadelumab or its components
* Participant (greater than or equal to \>or=6 years) and/or caregiver is willing to self-administer lanadelumab at home and has received documented training on self-administration during the SHP643-301 (SPRING) Study
For Female participants of childbearing potential only:
* Participant has agreed to be abstinent or agreed to comply with the applicable contraceptive requirements of this protocol for the duration of the expanded access program and for 70 days after completion
* Participant is not pregnant or breast-feeding Note: Participants who do not satisfy the above criteria will be excluded.
TAK-743-5012 Study (Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)):
* Participant has completed the treatment period of the TAK-743-3001 study (all Visit 14 assessments have been completed).
* Participant is demonstrating continued benefit from lanadelumab treatment.
* Participant and/or a parent(s)/legal guardian is informed of the nature of the expanded access program and can provide written informed consent for themselves or the child to participate (with assent from child when appropriate) prior to treatment).
* Participant does not have any condition including lab test that in the opinion of the Investigator may compromise their safety.
* Participant does not have a known hypersensitivity to lanadelumab or its components.
* Participant and/or caregiver is willing to self-administer lanadelumab at home and has received documented training on self-administration during the Study TAK-743-3001 OR the participant and/or caregiver is willing to self-administer lanadelumab at home and will receive training at the first two dose administrations in accordance with protocol.
Female Participants of childbearing potential only:
* Participant has agreed to be abstinent or agreed to comply with the applicable contraceptive requirements of this protocol for the duration of the expanded access program and for 70 days after completion of the last dose.
* Participant is not pregnant or breast-feeding.
Male Participants only:
* Participant has agreed to comply with the applicable contraceptive requirements of this protocol for the duration of the expanded access program and for 70 days following the last dose of lanadelumab
* Participant has agreed to not donate sperm during the course of the program and for 70 days following the last dose of lanadelumab.
2 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda Development Center Americas, Inc.
INDUSTRY
Shire
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Research of Arizona
Scottsdale, Arizona, United States
AIRE Medical of Los Angeles
Santa Monica, California, United States
Allergy & Asthma Clinical Research
Walnut Creek, California, United States
Henry J. Kanarek- Allergy, Asthma & Immunology
Overland Park, Kansas, United States
Institute Asthma and Allergy
Chevy Chase, Maryland, United States
Institute For Asthma and Allergy
Chevy Chase, Maryland, United States
University of Michigan Allergy and Immunology Specialty Clinic
Ann Arbor, Michigan, United States
Hudson-Essex Allergy
Belleville, New Jersey, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Clinical Research Center of Charlotte
Charlotte, North Carolina, United States
Bernstein Clinical Research Center
Cincinnati, Ohio, United States
Optimed Research, LTD
Columbus, Ohio, United States
Toledo Institute of Clinical Research Asthma & Allergy Center
Toledo, Ohio, United States
AARA Research Center
Dallas, Texas, United States
Yang Medicine
Ottawa, Ontario, Canada
Charité - Universitätsmedizin Berlin.
Berlin, , Germany
Klinikum der Johann-Wolfgang Goethe-Universitat.
Frankfurt, , Germany
Hämophilie Zentrum Rhein Main GmbH
Mörfelden-Walldorf, , Germany
Semmelweis Egyetem.
Budapest, , Hungary
Hospital Universitario La Paz. Paseo de la Castellana
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain more information on the study, click here/on this link
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TAK-743-5012
Identifier Type: OTHER
Identifier Source: secondary_id
TAK-743-6001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.